IXAZOMIB CITRATE
| Brand name | NINLARO |
|---|---|
| Active ingredient | IXAZOMIB CITRATE |
| Strength | EQ 2.3MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | November 2015 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 7442830 | November 2029 | substance, product |
| 9175017 | June 2029 | use U-2434 |
| 8859504 | June 2029 | substance, product |
| 8003819 | August 2027 | substance, product |
| 8871745 | August 2027 | use U-2434 |
| 8530694 | August 2027 | substance, product |
| 7687662 | August 2027 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.